Time toxicity in previously untreated metastatic or unresectable epidermal growth factor receptor-mutant non-small cell lung cancer: a clinical practice review.

ABSTRACT: The approvals of first-line therapies for patients with unresectable or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations have drastically improved survival outcomes. However, the healthcare-related burden for these regimens, particularly the concept of time toxicity, has not been fully understood. Our analysis of time toxicity, which measures healthcare days spent for treatments and treatment-related adverse events (TRAEs) in comparison to improved survival outcomes, highlights the urgent need for further research in this area. We analyzed phase III clinical trials for untreated NSCLC: FLAURA, FLAURA2, and MARIPOSA. Trial protocols were analyzed to calculate healthcare contact days. The time cutoff for analysis was the median treat

SUBMITTER: Jeon WJ 

PROVIDER: S-EPMC12605413 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature